Ticker

SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business.

GSK maintains a 'Strong Buy' rating, driven by robust Oncology portfolio growth and promising pipeline catalysts. The company's BLENREP is regaining traction in multiple myeloma, outperforming JNJ's DARZALEX in OS and potential label expansions to 2nd/1st-line settings. Mo-Rez [B7-H4 ADC] posted impressive phase 1 response rates in endometrial and platinum-resistant ovarian cancers, supporting five global pivotal…

GSK PLC Sponsored ADR (NYSE: GSK - Get Free Report) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling 16,061,751 shares, an increase of 29.7% from the March 15th total of 12,381,329 shares. Approximately 0.9% of the company's shares are sold short. Based on

Airlines are cutting global flight schedules for April and May as Iran-driven energy disruptions elevate fuel costs and operational uncertainty. Tesla (TSLA) secured its first European approval for Full Self-Driving Supervised in the Netherlands, signaling potential for broader EU adoption.

British drugmaker GSK's experimental targeted cancer drug Mo-rez has blockbuster potential, its head of oncology research has told reporters, after early data showed the drug helped ​shrink tumors in patients with advanced, hard-to-treat cancers.